Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most
common chronic liver disease globally, affecting more than a third of the world's adult …

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the
paucity of human-relevant models for target discovery and compound screening. Here we …

With the aging of global population, the incidence of nonalcoholic fatty liver disease
(NAFLD) has surged in recent decades. NAFLD is a multifactorial disease that follows a …

The acronym nonalcoholic fatty-liver disease (NAFLD) groups a heterogeneous patient
population. Although in many patients the primary driver is metabolic dysfunction, a complex …

Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic fat accumulation in the
absence of excessive alcohol consumption and is strongly associated with obesity, type 2 …

Nonalcoholic steatohepatitis (NASH) is a burgeoning global health crisis that mirrors the
obesity pandemic. This global health crisis has stimulated active research to develop novel …

Primary nonalcoholic fatty liver disease (NAFLD) is bi-directionally associated with the
metabolic syndrome and its constitutive features (“factors”: impaired glucose disposal …

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease.
NAFLD often occurs associated with endocrinopathies. Evidence suggests that endocrine …

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic-dysfunction-
associated fatty liver disease (MAFLD), affects a quarter of the worldwide population. Natural …